The clinical efficacy of osimertinib for the treatment of patients with advanced EGFR-mutated NSCLC who had experienced disease progression during prior therapy with EGFR-TKIs was first documented in the international Phase 1/2 AURA trial.7 In this study, osimertinib achieved an ORR of 61% (95% confidence interval [CI]: 52–70) among patients with centrally confirmed T790M mutations (n = 127). Here, EGFR is linked to non-small cell lung carcinoma.